Stellular Bio develops regenerative biologic therapies for ocular surface diseases, focusing on a platelet-derived therapy to improve patient quality of life. The company is also pioneering a platform for producing allogeneic, stem-cell-derived platelet-like cells, offering a versatile approach in regenerative medicine.
Funding
Funding not disclosed
Founders
Product
Problem
Ocular surface diseases (OSD) are complex conditions affecting millions, often leading to tear film dysfunction, potential corneal damage, and vision loss. Current treatments may not fully address the underlying regenerative needs of the ocular surface, particularly in severe cases or those associated with conditions like Sjogren's syndrome. The increasing prevalence of OSD, driven by factors like increased screen time and an aging population, necessitates more effective and scalable therapeutic solutions.
Solution
Stellular Bio is developing a platelet-derived regenerative biologic (PRB) therapy designed to improve the lives of patients with OSD. Their PRB leverages the regenerative potential of platelet-rich plasma (PRP) while offering the advantages of a well-characterized, reproducible, and scalable engineered product. The proprietary manufacturing process ensures the therapy retains the polypharmacology of active substances from platelets and is donor plasma-independent. Stellular Bio's PRB is designed to address the complex interactions of multiple structures and tissues involved in tear film function and disease, offering a versatile approach to regenerative medicine in ophthalmology. The company is initially pursuing clinical proof of concept in Sjogren's syndrome-related dry eye, with plans to expand into the broader OSD market.
Target Audience
The primary target audience includes patients suffering from ocular surface diseases, particularly those with Sjogren's syndrome-related dry eye, and ophthalmologists seeking advanced regenerative therapies for their patients.
Features
- Platelet-derived regenerative biologic (PRB) that retains the polypharmacology of hundreds of active substances from platelets.
- Proprietary PRB manufacturing process that is well-characterized and reproducible.
- Off-the-shelf, donor plasma-independent PRB production.
- PRB production tunable via induced pluripotent stem cell (iPSC) engineering.
- Scalable manufacturing methods to enable clinical trials and commercial production.